Novel Technologies Initiative

Sensor Technologies to Monitor Inflammation in IBD - RFP

Overview: Crohn’s & Colitis Foundation has recognized the necessity to advance research focused on novel technologies to address unmet clinical needs in IBD, particularly relating to continuous or periodic monitoring of inflammation in IBD.

Scope: The purpose of this initiative is to support the development of sensor technologies that can be implemented to detect and monitor inflammation in the context of IBD. Proposed technology should meet the following criteria:

  • Minimally invasive detection of active inflammation. Preferably, the signals detected should be related to biological processes regarded to be causative and/or highly corelated with intestinal inflammation in IBD (e.g. cytokine levels, presence of proinflammatory immune cells, proinflammatory mediators, etc.) and should be informative with respect to symptoms (e.g. active "flare-up" prior to observation of severe symptoms).
  • Sampling of data should be continuous or periodic during daily life, specifically, technologies, such as sensors/ biosensors/ nano-sensors, implantable, ingestible, wearable or environmental devices, will be considered.
  • Have the potential to reach clinical studies within the next 3-4 years.

Eligibility: The Principal Investigator (PI) must be a faculty member actively conducting research in the area of sensor technologies for healthcare applications. If the PI does not have experience in IBD research, collaborators with experience in IBD should be identified as needed to support the project objectives. At the time of application, the PI must be employed by an institution (public non-profit, private non-profit, or government). US and international researchers are encouraged to apply.

Funding Terms: $125,000 for one year (inclusive of 10% indirect cost)

Application Deadline: September 7, 2018

How to apply

Applications are not currently being accepted for this RFP. Please check this page for updates starting June 2019.

Questions? Contact Dr. Gerard Honig at